MCRB · Seres Therapeutics, Inc.
$4.54
+0.06 (+1.34%)
At close · Aug 14
Going-concern doubt
— flagged Aug 5, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We have identified conditions and events that raise substantial doubt regarding our ability to continue as a going concern.”View the 10-Q filed Aug 5, 2026
Market Cap
$45.13M
Shares
9.94M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Eric D. Shaff | Former President and Chief Executive Officer | $1,775,549 |
| Thomas J. DesRosier | Former Co-President and Co-Chief Executive Officer and current Executive Vice President and Chief Legal Officer | $1,136,023 |
| Teresa Young | Former Executive Vice President and Chief Commercial and Strategy Officer | $1,021,462 |
| Matthew Henn | President and Chief Scientific Officer | $1,014,347 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Eric D. Shaff | President and Chief Executive Officer | $2,682,007 |
| Lisa von Moltke | Executive Vice President and Chief Medical Officer | $1,270,353 |
| Thomas J. DesRosier | Executive Vice President and Chief Legal Officer | $1,248,507 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Eric D. Shaff | President and Chief Executive Officer | $3,158,336 |
| Teresa Young | Executive Vice President, Chief Commercial and Strategy Officer | $1,820,458 |
| Lisa von Moltke | Executive Vice President and Chief Medical Officer | $1,571,141 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Eric D. Shaff | President and Chief Executive Officer | $4,006,248 |
| David Arkowitz | Executive Vice President, Chief Financial Officer and Head of Business Development | $1,786,650 |
| Lisa von Moltke | Executive Vice President and Chief Medical Officer | $1,734,614 |
| Matthew Henn | Executive Vice President and Chief Scientific Officer | $1,672,303 |
| Paula A. Cloghessy | Executive Vice President and Chief People Officer | $1,632,966 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Eric D. Shaff | President and Chief Executive Officer | $9,711,680 |
| David Arkowitz | Executive Vice President, Chief Financial Officer and Head of Business Development | $5,226,695 |
| Matthew Henn | Executive Vice President and Chief Scientific Officer | $3,551,792 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| David S. Ege | Executive Vice President and Chief Technology Officer | $5,318,587 |
| Eric D. Shaff | President and Chief Executive Officer | $3,135,900 |
| Thomas J. DesRosier | Executive Vice President, Chief Legal Officer and Secretary | $1,437,260 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Eric D. Shaff | President and Chief Executive Officer | $2,032,548 |
| Thomas J. DesRosier | Executive Vice President, Chief Legal Officer and Secretary | $977,341 |
| Matthew Henn | Executive Vice President and Chief Scientific Officer | $859,452 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Roger J. Pomerantz | Former President and Chief Executive Officer | $3,018,060 |
| Thomas J. DesRosier | Chief Legal Officer, Executive Vice President, and Secretary | $1,839,330 |
| Eric D. Shaff | President and Chief Executive Officer | $1,447,070 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Richard N. Kender | Class II director to serve until the 2029 Annual Meeting of Stockholders, and until their respective successors have been duly e | Appointed | 2026-07-08 |
| Claire M. Fraser, Ph.D. | Class II director to serve until the 2029 Annual Meeting of Stockholders, and until their respective successors have been duly e | Appointed | 2026-07-08 |
| Stephen A. Berenson | Class II director to serve until the 2029 Annual Meeting of Stockholders, and until their respective successors have been duly e | Appointed | 2026-07-08 |
| Hans-Juergen Woerle, M.D., Ph.D. | member of the board of directors | Resigned | 2026-06-01 |
| Kelly Brady, M.S. | Executive Vice President, Chief Operating Officer | Appointed | 2026-03-02 |
| Matthew Henn, Ph.D. | President | Appointed | 2026-03-02 |
| Richard N. Kender | Interim Chief Executive Officer | Appointed | 2026-03-02 |
| Marella Thorell | Co-Chief Executive Officers and Co-Presidents | Appointed | 2025-07-22 |
| Thomas J. DesRosier | Co-Chief Executive Officers and Co-Presidents | Appointed | 2025-07-22 |
| Eric D. Shaff | President and Chief Executive Officer | Resigned | 2025-07-22 |
| Lisa von Moltke, M.D. | Executive Vice President and Chief Medical Officer | Resigned | 2025-02-27 |
| Hans-Juergen Woerle, M.D. | Class III director | Appointed | 2025-02-06 |
| Eric Shaff | interim principal accounting officer | Appointed | 2024-02-26 |
| David Arkowitz | Executive Vice President and Chief Financial Officer | Retired | 2024-02-26 |
| Marella Thorell | principal accounting officer | Appointed | 2024-02-26 |
| Marella Thorell | Executive Vice President and Chief Financial Officer | Appointed | 2024-02-26 |
| Grégory Behar | board of directors | Resigned | 2023-10-04 |
| Claire Fraser, Ph.D. | Class II director | Appointed | 2023-01-05 |
Key facts
CIK
1609809
CUSIP
81750R201
13F (30d)
37 filings
37 filers
Visit website
Investor relations